Croda introduces new bioprocessing solutions to replace banned materials
30 August 2023: Croda has introduced a range of new bioprocessing aids called Virodex™, which provide an answer to the key market need for replacing the popular, but now banned, bioprocessing detergent, Triton™ X-100.
Key changes in REACH regulations have meant that Triton™ X-100, the bioprocessing detergent, can no longer be used in Europe, and globally, manufacturers recognise the need to act now to find suitable replacements.
As it stands today, there are limited suitable and sustainable replacement options, especially those that are cGMP and readily available, creating an urgent need for replacement options. To address this market requirement, Croda’s Pharma business has developed its REACH-compliant Virodex™ products, offering a sustainable and cGMP solution.
James Lawrence, Global Business Director, Small Molecule and Protein Delivery, for Croda’s Pharma business, said:
“Empowering biologics delivery is our promise, and Virodex™ is our proof. As we continue to expand our manufacturing capabilities, partnerships, acquisitions, and more – this product range is a great example of us innovating with our customers, giving them not just a sustainable alternative to Triton™ X-100 but a replacement backed by comprehensive performance data.”
Commenting, Steve Mellor, Research and Technology Director, Croda Life Sciences, said:
“Our teams across the globe have been focused on continually developing new and exciting solutions. Networking, global collaboration, and true transparency between different expert groups within Croda continues to drive great innovation, and products like Virodex™ are proof of that.”
Croda’s Pharma business is a leading partner in the development of delivery systems and solutions for biologics. Croda’s platforms enable the next generation of vaccines and therapeutics. Through acquisition of Avanti Polar Lipids in 2020, Croda was the first company to supply clinical and commercial quantities of critical lipid systems to support the roll-out of COVID-19 vaccines globally.
Recently, the company also shared news of a cooperative agreement with the US government to expand domestic manufacturing of critical vaccines and therapeutics, an acquisition of the innovative biotechnology company, Solus Biotech based in South Korea, and two new partnerships for advancing vaccine adjuvant capabilities and sustainable solutions.
For enquiries contact:
About Croda Pharma's business - www.crodapharma.com
Croda’s Pharma business is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its Adjuvant Systems, Small Molecule, Protein, and Nucleic Acid delivery platforms.
About Croda - www.croda.com
Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world’s most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere. Croda is a FTSE 100 company with over 6,100 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™. As part of this Purpose, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030. Following an agreement to divest the majority of its industrial-focused Performance Technologies and Industrial Chemicals businesses, Croda is well on the way to becoming a ‘pure-play’ Consumer Care and Life Sciences company.
Triton is a trademark of The Dow Chemical Company or an affiliated company of Dow.